Shares of Astrazeneca PLC (NYSE:AZN) hit a new 52-week high during trading on Friday . The company traded as high as $35.04 and last traded at $34.47, with a volume of 7,132,119 shares changing hands. The stock had previously closed at $34.30.

A number of analysts have commented on AZN shares. Goldman Sachs Group Inc. cut shares of Astrazeneca PLC from a “neutral” rating to a “sell” rating in a research report on Monday, April 11th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Astrazeneca PLC in a report on Thursday, April 21st. Bank of America Corp. reiterated a “buy” rating and set a $36.65 price objective on shares of Astrazeneca PLC in a report on Monday, July 18th. Shore Capital reiterated a “hold” rating on shares of Astrazeneca PLC in a report on Tuesday, June 14th. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Thursday, July 28th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $36.71.

The company has a market capitalization of $86.73 billion and a PE ratio of 39.18. The firm’s 50-day moving average price is $30.72 and its 200-day moving average price is $29.69.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.76 by $0.07. The business had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.56 billion. The company’s revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.21 EPS. On average, analysts anticipate that Astrazeneca PLC will post $2.47 earnings per share for the current fiscal year.

The company also recently announced a dividend, which will be paid on Monday, September 12th. Shareholders of record on Friday, August 12th will be issued a $0.44 dividend. The ex-dividend date is Wednesday, August 10th.

A number of hedge funds and institutional investors have recently modified their holdings of the company. Genesee Valley Trust Co. boosted its position in shares of Astrazeneca PLC by 5.4% in the fourth quarter. Genesee Valley Trust Co. now owns 31,627 shares of the company’s stock valued at $1,074,000 after buying an additional 1,617 shares during the period. Morgan Stanley boosted its position in shares of Astrazeneca PLC by 16.3% in the fourth quarter. Morgan Stanley now owns 1,572,388 shares of the company’s stock valued at $53,382,000 after buying an additional 220,787 shares during the period. Westfield Capital Management Co. LP boosted its position in shares of Astrazeneca PLC by 11.8% in the fourth quarter. Westfield Capital Management Co. LP now owns 213,350 shares of the company’s stock valued at $7,243,000 after buying an additional 22,450 shares during the period. US Bancorp DE boosted its position in shares of Astrazeneca PLC by 8.2% in the fourth quarter. US Bancorp DE now owns 126,767 shares of the company’s stock valued at $4,304,000 after buying an additional 9,638 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Astrazeneca PLC by 7.6% in the fourth quarter. Wells Fargo & Company MN now owns 2,009,893 shares of the company’s stock valued at $68,236,000 after buying an additional 141,767 shares during the period.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.